Literature DB >> 31377021

Chemosensitivity and chemoresistance in endometriosis - differences for ectopic versus eutopic cells.

Darja Lavogina1, Külli Samuel2, Arina Lavrits3, Alvin Meltsov2, Deniss Sõritsa4, Ülle Kadastik5, Maire Peters6, Ago Rinken7, Andres Salumets8.   

Abstract

RESEARCH QUESTION: Endometriosis is a common gynaecological disease defined by the presence of endometrium-like tissue outside the uterus. This complex disease, often accompanied by severe pain and infertility, causes a significant medical and socioeconomic burden; hence, novel strategies are being sought for the treatment of endometriosis. Here, we set out to explore the cytotoxic effects of a panel of compounds to find toxins with different efficiency in eutopic versus ectopic cells, thus highlighting alterations in the corresponding molecular pathways.
DESIGN: The effect on cellular viability of 14 compounds was established in a cohort of paired eutopic and ectopic endometrial stromal cell samples from 11 patients. The biological targets covered by the panel included pro-survival enzymes, cytoskeleton proteins, the proteasome and the cell repair machinery.
RESULTS: Protein kinase inhibitors GSK690693, ARC-775 and sorafenib, proteasome inhibitor bortezomib, and microtubule-depolymerizing toxin monomethyl auristatin E were more effective in eutopic cells. In contrast, 10 µmol/l of the anthracycline toxin doxorubicin caused cellular death in ectopic cells more effectively than in eutopic cells. The large-scale sequencing of mRNA isolated from doxorubicin-treated and control cells indicated different survival strategies in eutopic versus ectopic endometrium.
CONCLUSIONS: Overall, the results confirm evidence of large-scale metabolic reprogramming in endometriotic cells, which underlies the observed differences in sensitivity towards toxins. The enhanced efficiency of doxorubicin interfering with redox equilibria and/or DNA repair mechanisms pinpoints key players that can be potentially used to selectively target ectopic lesions in endometriosis.
Copyright © 2019 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cell viability; Doxorubicin; Endometriosis; Eutopic/ectopic endometrial stromal cell; Protein kinase inhibitor; Toxin

Year:  2019        PMID: 31377021     DOI: 10.1016/j.rbmo.2019.05.019

Source DB:  PubMed          Journal:  Reprod Biomed Online        ISSN: 1472-6483            Impact factor:   3.828


  4 in total

1.  The potential of glioma-associated oncogene homolog 1 (GLI1) as a therapeutic target in endometriosis.

Authors:  Konstantinos Nirgianakis; Marc Spaanderman; Boris W Kramer; Martin Mueller
Journal:  Ann Transl Med       Date:  2020-04

2.  Viability fingerprint of glioblastoma cell lines: roles of mitotic, proliferative, and epigenetic targets.

Authors:  Darja Lavogina; Tõnis Laasfeld; Markus Vardja; Helen Lust; Jana Jaal
Journal:  Sci Rep       Date:  2021-10-13       Impact factor: 4.379

3.  Revisiting the Resazurin-Based Sensing of Cellular Viability: Widening the Application Horizon.

Authors:  Darja Lavogina; Helen Lust; Maris-Johanna Tahk; Tõnis Laasfeld; Hans Vellama; Naila Nasirova; Markus Vardja; Kattri-Liis Eskla; Andres Salumets; Ago Rinken; Jana Jaal
Journal:  Biosensors (Basel)       Date:  2022-03-25

4.  Homing Peptide-Based Targeting of Tenascin-C and Fibronectin in Endometriosis.

Authors:  Lorena Simón-Gracia; Kristina Kiisholts; Vilma Petrikaitė; Allan Tobi; Merli Saare; Prakash Lingasamy; Maire Peters; Andres Salumets; Tambet Teesalu
Journal:  Nanomaterials (Basel)       Date:  2021-11-30       Impact factor: 5.076

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.